Product Pipeline Pipeline

Our Pipeline

Progenics has a pipeline that includes products in pre-clinical through late-stage development. We are focused on critical unmet diagnostic and therapeutic needs of prostate cancer patients.

PSMA Targeted Oncology

  • PSMA Targeted Imaging Compound

    Prostate / Imaging

    Progenics’ development stage radiopharmaceutical imaging agent, 1404, is a targeted radioactive substance that visualizes prostate cancer. The expression of PSMA by tumor cells offers the opportunity to “visualize cancer” by imaging 1404’s radioactive payload This is designed to allow for improved detection and staging, more precise biopsies, and a targeted treatment plan that utilizes active surveillance as a disease management tool. MORE>

  • PSMA ADC Therapeutic

    Prostate / Therapeutic

    Progenics’ PSMA ADC targeted therapeutic is in a Phase II clinical trial of men with advanced prostate cancer. PSMA ADC is an antibody-drug conjugate that targets prostate specific membrane antigen, a protein expressed on the surface of almost all prostate cancer tumor cells and in the neovasculature that supplies many other tumors.  Our targeted therapeutic seeks out and kills cancer cells with minimal damage to surrounding healthy tissue.  MORE>

  • PSMA Targeting Small Molecule Therapeutic

    Prostate / Therapeutic

    Progenics’ targeted small molecule radiotherapeutic program is in preclinical development for the treatment of metastatic prostate cancer. The program is designed to deliver lethal doses of beta- emissions to prostate cancer cells while causing minimal damage to healthy surrounding tissue. MORE>


  • Azedra

    SPA Pheochromocytoma / Neuroblastoma / Neuroendocrine

    Progenics’ late stage ultra-orphan drug candidate, Azedra, is being developed for the treatment of malignant pheochromocytoma, a rare adrenal tumor.  The development is being conducted under a Special Protocol Assessment which may accelerate FDA review and marketing approval decisions.

  • Kinase

    Solid Tumors

    Progenics’ kinase program seeks to intercept signals that cancer cells rely on to grow and divide.  We have discovered novel small molecules that are undergoing lead optimization.

Oncology Supportive Care

  • Relistor SC (AI)

    OIC Advanced Illness

    RELISTOR subcutaneous injection, a small-molecule mu-opioid receptor antagonist, is approved in the United States for the treatment of opioid induced constipation in patients with advanced illness. Progenics has licensed Relistor to Salix Pharmaceuticals in markets worldwide other than Japan, where Ono Pharmaceuticals is conducting clinical trials of subcutaneous Relistor in advanced illness patients.

  • Relistor SC (CP)

    OIC Chronic Pain

    Results of a phase 3 trial of Relistor SC in chronic pain patients showed statistically significant improvements over placebo in rescue free bowel movements (RFBMs) within 4 hours of injection, time to first RFBM, and increase in weekly RFBMs from baseline.  After an FDA Complete Response Letter last year for a sNDA for this indication, Salix and Progenics are working with regulatory agencies to define a path for regulatory approval in this patient population.

  • Relistor SC (AI-Japan)

    OIC Advanced Illness

    Ono Pharmaceuticals licensed Relistor for Japan and is in clinical trials in advanced illness.

  • Relistor Oral

    OIC Chronic Pain

    A completed phase 3 trial of oral Relistor has shown a highly significant improvement in RFBM within 4 hours of dosing and in laxation response over 4 weeks.  In light of last year’s CRL, Salix and Progenics is working with regulatory agencies to define a path for marketing approval of this formulation.

Partnered Programs

  • PRO 140

    HIV Viral Entry Inhibitor

    PRO 140 is a humanized anti-CCR5 monoclonal antibody created at Progenics and now developed by CytoDyn Inc.  PRO 140 is in Phase 2 testing as a treatment for human immunodeficiency virus (HIV) infection.  MORE>

  • PRO 391

    Antibodies Targeting C.diff Toxins

    C. difficile is a pair of humanized antibodies that neutralize the disease-causing toxins of Clostridium difficile.  PRO 391 provides a non-antibiotic approach to managing this important and life-threatening disease.  MORE>